Full metadata record
DC FieldValueLanguage
dc.contributor.advisorLecanda, F. (Fernando)-
dc.creatorPerurena, N. (Naiara)-
dc.date.accessioned2016-05-03T07:52:43Z-
dc.date.available2016-05-03T07:52:43Z-
dc.date.issued2015-08-27-
dc.date.submitted2015-09-03-
dc.identifier.citationPERURENA, Naiara. “Role of EPCR in breast cancer progression and metastasis”. Lecanda, Fernando. Tesis doctoral. Universidad de Navarra, Pamplona, 2015es_ES
dc.identifier.urihttps://hdl.handle.net/10171/40477-
dc.description.abstractEndothelial protein C receptor (EPCR) is a transmembrane receptor widely expressed in endothelial cells where it exerts cytoprotective and anticoagulant activities. It is also expressed in lung tumor cells where EPCR promotes tumor cell survival and increases metastatic activity. However, to date the contribution of EPCR to tumorigenesis and metastasis in breast cancer remains ill defined. Global expression analysis in a cohort of 286 breast cancer patients revealed that patients with high EPCR expression levels have significantly shorter relapse-free survival times. In vitro, stimulation with activated protein C (APC) or shRNA-mediated EPCR silencing did not alter growth kinetics of bone metastatic human breast cancer cells in basal or pro-apoptotic conditions. However, subcutaneous and orthotopic inoculation of control and EPCR-silenced (shEPCR) bone metastatic cells showed a marked reduction in tumor growth, while markers of cell growth, apoptosis and angiogenesis were unaffected. EPCR effects on tumorigenesis were independent of heterotypic tumor-stroma interactions, including fibroblasts and immune cells. Interestingly, EPCR silencing led to a substantial reduction in skeletal metastatic burden and osteolytic lesions in an intracardiac inoculation model, compared to control cells. Moreover, EPCR silencing reduced tumor bone colonization in a model of intratibial injection. Furthermore, lung metastasis was blocked in another in vivo model of metastasis when EPCR was silenced in murine breast tumor cells, despite their similar growth kinetics in vitro. Transcriptomic analysis of tumors identified SPOCK1 as the most robustly downregulated gene in EPCR-silenced tumors. Furthermore, SPOCK1 expression levels were associated with high EPCR expression levels in breast cancer patients and correlated with shorter relapse-free survival times in a subset of breast cancer patients. These data indicate that EPCR is a clinically relevant factor in breast cancer, which promotes primary tumor growth and metastatic activity in target organs, including the skeleton and lungs. Taken together, these data suggest that EPCR represents a potential therapeutic target in breast cancer metastasis.es_ES
dc.language.isospaes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectBiología celulares_ES
dc.subjectBiología moleculares_ES
dc.subjectCarcinogenésises_ES
dc.subjectMaterias Investigacion::Ciencias de la Saludes_ES
dc.titleRole of EPCR in breast cancer progression and metastasises_ES
dc.typeTesises_ES

Files in This Item:
Thumbnail
File
TESIS_NAIARA PERURENA.pdf
Description
Size
6.39 MB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.